Journal of Shanghai Jiao Tong University (Medical Science) >

2021 , Vol. 41 >Issue 2: 129 - 133

DOI: https://doi.org/10.3969/j.issn.1674-8115.2021.02.001

Basic research

Protective effect of pituitary adenylate cyclase-activating polypeptide 38 on acute radiation-induced myocardial injury

  • Huan LI ,
  • Pei-qiang YI ,
  • Jun SU ,
  • Pei-zhan CHEN ,
  • Cheng XU ,
  • Lu CAO ,
  • Jia-yi CHEN ,
  • Min LI
Expand
  • 1.Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
    2.Clinical Research Center, Ruijin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai 201801, China

Received date: 2020-06-01

  Online published: 2021-02-28

Supported by

National Key Research and Development Program of China(2016YFC0105409);National Natural Science Foundation of China(81602791);Scientific and Technological Innovation Action Plan of Science and Technology Commission of Shanghai Municipality(19411950900);Shanghai Municipal Education Commission—Gaofeng Clinical Medicine Grant Support(20171904)

Fold

Abstract

Objective

·To explore the effect of pituitary adenylate cyclase-activating polypeptide 38 (PACAP38) on radiosensitivity of myocardial cells and its potential protective effect on acute radiation-induced myocardial injury.

Methods

·The radiation-related cardiac injury models were established by using 6 MV X-ray with H9C2 cardiomyocytes and male C57BL/6J mice which were pre-treated with different doses of PACAP38 prior to radiation exposure. H9C2 cells were treated with 10-9 and 10-7 mol/L PACAP38 2 h before irradiation. 10 μg of 0.1 μg/μL PACAP38 was administered to C57BL/6J mice intraperitoneally at 2 h before irradiation and additional doses were given at 24 h and 48 h after irradiation. In vivo and in vitro myocardial radiation injury models were divided into control group, PACAP38 group, irradiation group (IR) and PACAP38+IR group. The specific irradiation doses in vitro were 2, 4, 8 and 12 Gy. The specific irradiation dose in vivo were 14 Gy, one fraction irradiation. CCK-8 and clonogenesis assays were used to examine cell viability and radiosensitivity, respectively. Hematoxylin and eosin staining was used to evaluate the pathological changes of myocardial tissue in mice after one-month irradiation.

Results

·The cell viability of H9C2 cardiomyocytes pretreated with PACAP38 was significantly higher than that of irradiation (12 Gy) alone [10-7 mol/L PACAP38+IR group vs IR group, (98.63±2.70)% vs (83.67±0.78)%, P=0.000]. The survival fraction at 2 Gy increased from 0.53 to 0.63 and 0.70 after 10-9 and 10-7 mol/L PACAP38 pretreatment, and the sensitivity enhancement ratio of 10-9 and 10-7 mol/L PACAP38 pretreatment groups were 0.95 and 0.91, respectively. In vivo studies showed that PACAP38 could significantly alleviate the pathological damage of myocardial tissue after irradiation (14 Gy), including cardiomyocyte degeneration, eosinophilic enhancement, cytoplasmic vacuolation, nuclear pyknosis and myocardial fiber distortion.

Conclusion

·PACAP38 can significantly reduce the radiosensitivity of myocardial cells and has a certain protective effect on acute radiation-induced myocardial injury.

Key words： pituitary adenylate cyclase-activating polypeptide 38 (PACAP38); irradiation model; radiation-induced myocardial injury; cardioprotectant

Cite this article

Huan LI , Pei-qiang YI , Jun SU , Pei-zhan CHEN , Cheng XU , Lu CAO , Jia-yi CHEN , Min LI . Protective effect of pituitary adenylate cyclase-activating polypeptide 38 on acute radiation-induced myocardial injury[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2021 , 41(2) : 129 -133 . DOI: 10.3969/j.issn.1674-8115.2021.02.001

References

1 Delaney G, Jacob S, Featherstone C, et al. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines[J]. Cancer, 2005, 104(6): 1129-1137.
2 van Nimwegen FA, Schaapveld M, Janus CPM, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk[J]. JAMA Intern Med, 2015, 175(6): 1007-1017.
3 van Nimwegen FA, Ntentas G, Darby SC, et al. Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines[J]. Blood, 2017, 129(16): 2257-2265.
4 Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials[J]. Lancet, 2005, 366(9503): 2087-2106.
5 McGale P, Darby SC, Hall P, et al. Incidence of heart disease in 35 000 women treated with radiotherapy for breast cancer in Denmark and Sweden[J]. Radiother Oncol, 2011, 100(2): 167-175.
6 Desai MY, Jellis CL, Kotecha R, et al. Radiation-associated cardiac disease: a practical approach to diagnosis and management[J]. JACC Cardiovasc Imaging, 2018, 11(8): 1132-1149.
7 Vaudry D, Falluel-Morel A, Bourgault S, et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery[J]. Pharmacol Rev, 2009, 61(3): 283-357.
8 Farnham MMJ, Inglott MA, Pilowsky PM. Intrathecal PACAP-38 causes increases in sympathetic nerve activity and heart rate but not blood pressure in the spontaneously hypertensive rat[J]. Am J Physiol Heart Circ Physiol, 2011, 300(1): H214-H222.
9 Khan AM, Li M, Brant E, et al. Renoprotection with pituitary adenylate cyclase-activating polypeptide in cyclosporine A-induced nephrotoxicity[J]. J Investig Med, 2011, 59(5): 793-802.
10 Kouvaris JR, Kouloulias VE, Vlahos LJ. Amifostine: the first selective-target and broad-spectrum radioprotector[J]. Oncologist, 2007, 12(6): 738-747.
11 Demiral AN, Yerebakan O, Sim?ir V, et al. Amifostine-induced toxic epidermal necrolysis during radiotherapy: a case report[J]. Jpn J Clin Oncol, 2002, 32(11): 477-479.
12 van der Veen SJ, Ghobadi G, de Boer RA, et al. ACE inhibition attenuates radiation-induced cardiopulmonary damage[J]. Radiother Oncol, 2015, 114(1): 96-103.
13 Reglodi D, Vaczy A, Rubio-Beltran E, et al. Protective effects of PACAP in ischemia[J]. J Headache Pain, 2018, 19(1): 19.
14 Racz B, Reglodi D, Horvath G, et al. Protective effect of PACAP against doxorubicin-induced cell death in cardiomyocyte culture[J]. J Mol Neurosci, 2010, 42(3): 419-427.
15 Seaborn T, Masmoudi-Kouli O, Fournier A, et al. Protective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) against apoptosis[J]. Curr Pharm Des, 2011, 17(3): 204-214.
16 Kim EJ, Lee J, Jung YR, et al. Involvement of corin downregulation in ionizing radiation-induced senescence of myocardial cells[J]. Int J Mol Med, 2015, 35(3): 731-738.
17 Dai C, He L, Ma B, et al. Facile nanolization strategy for therapeutic Ganoderma lucidum spore oil to achieve enhanced protection against radiation-induced heart disease[J]. Small, 2019, 15(36): e1902642.
18 Lauk S, Kiszel Z, Buschmann J, et al. Radiation-induced heart disease in rats[J]. Int J Radiat Oncol Biol Phys, 1985, 11(4): 801-808.
19 Hoving S, Heeneman S, Gijbels MJJ, et al. Single-dose and fractionated irradiation promote initiation and progression of atherosclerosis and induce an inflammatory plaque phenotype in ApoE-/- mice[J]. Int J Radiat Oncol Biol Phys, 2008, 71(3): 848-857.
20 Rezaeyan A, Haddadi GH, Hosseinzadeh M, et al. Radioprotective effects of hesperidin on oxidative damages and histopathological changes induced by X-irradiation in rats heart tissue[J]. J Med Phys, 2016, 41(3): 182-191.
Options
Outlines

/

〈 〉